AGP Executive Report

Cardiology Research Roundup (ESC 2026): A preview of major European Society of Cardiology Congress trials in Munich highlights studies that could shift how clinicians manage cardiovascular risk and treatment decisions. Inflation & Health Costs: Switzerland’s July inflation eased, with healthcare goods and services flat year-on-year, while the report notes that household insurance premiums can still rise even when the “healthcare” CPI component looks calm. Nutrition Trend: Allulose is getting more attention as a “rare sugar” option for reducing sugar without spiking blood glucose, though high intake may cause digestive upset. MedTech/AI Funding: Eyedentity secured €1.3m to help detect deadly eye cancer earlier using AI, aiming to expand into opticians, clinics and hospitals. Public Health & Safety: Two Belgian hikers’ bodies were found after decades missing as a Swiss glacier melted, underscoring how climate change is reshaping risk and recovery efforts. Swiss Healthcare Policy: Canton Vaud plans to withdraw emergency aid from around 40 Ukrainians after rejected S-permit applications, drawing criticism from rights groups. Work-Life Policy: Zurich approved a framework for a 35-hour working week pilot, with details still to be assigned by department. Local Emergency: A major fire in Thusis destroyed a restaurant with apartments; five people are missing and eight were injured, with investigations underway. Clinical Insight (MS): New University Hospital Basel research links retinal thinning on OCT to later cognitive decline in multiple sclerosis, independent of relapse activity. Pharma Expansion: Roche will invest $750m to double injectable manufacturing capacity in Oregon, expanding its US production footprint. Health Tech in Trials: UTMB expanded anti-doping testing to all runners in its finals races, increasing testing volume as the sport grows.

Female Athlete Health Push: The Global Alliance for Female Athletes (GAFA) expands from four to nine nations, adding Canada, France, Germany, Japan and Switzerland, aiming to close research gaps and improve support for women in sport and sports medicine. Swiss Trade Update: Switzerland and China have agreed an updated free trade deal, with 99.8% of Swiss exports entering China duty free, covering services, digital trade and cooperation—important for Swiss pharma and chemicals. Dental Innovation in Switzerland: Curodont, a noninvasive cavity treatment developed in Switzerland, is being rolled out in Wellington, using remineralization (no drills or needles) for early tooth decay. Cancer Risk Study: A study links high intake of nitrites found in leafy greens (like rocket and Swiss chard) to up to a 50% higher bowel cancer risk in men, raising questions about dietary sources beyond processed meats. Eye-Care Deal for Europe/Switzerland: Lupin’s VISUfarma signs a licensing agreement to commercialize YUVEZZI eye drops for presbyopia across the EU plus the UK, Switzerland, Norway and Iceland. Roche Manufacturing Expansion: Roche/Genentech plans a $750M Oregon expansion to add fill-finish capabilities for drug-delivery devices, targeting operations in 2031.

Workforce & Pharma: CSL Behring says it has completed a Bern site transformation with job cuts “less than 10%” of staff, while creating 100+ new roles to limit layoffs. Health Policy & Rights: Swiss pro-life groups have launched a petition against a parliamentary move to fully fund abortions via mandatory health insurance from Jan. 1, 2027, arguing it undermines cost-containment and freedom of conscience. Climate & Public Health: As Swiss glaciers keep melting, Valais police report the remains of two Belgian mountaineers missing since 1992 were found on the Trift Glacier and identified by DNA. Eye Care Deal: Lupin’s VISUfarma has signed an exclusive licensing partnership to commercialise YUVEZZI eye drops for presbyopia across the EU, UK, Switzerland, Norway and Iceland. Trade & Industry: Switzerland’s exports rebounded in July, up 13.8% nominally, driven by chemicals and pharmaceuticals, while imports fell 4.5%, widening the trade surplus. SRHR & GBV Services: UNFPA and WHO launched a new Nepal programme (with Swiss support) to strengthen sexual and reproductive health and gender-based violence services across 20 municipalities.

Cancer Care & Innovation: Moderna and Merck report Phase 3 success for Intismeran, a personalized mRNA melanoma vaccine with Keytruda, but access may be limited because each dose needs bespoke tumor-based manufacturing. Swiss Health Policy: A commissioned report submitted to Switzerland’s Federal Office of Public Health supports ginkgo leaf extract for cognitive decline, with a coverage decision expected within the year. Clinical Trials (Lung Cancer): Taiho Oncology and Cullinan selected interim Phase 3 REZILIENT3 results for a lung cancer presidential symposium, testing zipalertinib plus chemotherapy for EGFR exon 20 insertion NSCLC. Rare Neurology (Trial Enrollment): IntraBio says its pivotal Phase III levacetylleucine trial for CACNA1A-related disorders is enrolling and aims to finish recruitment in October. Public Health & Rights (Nepal): UNFPA and WHO launch a two-year, $6M programme in Nepal to strengthen sexual and reproductive health and gender-based violence services. Climate & Health (Swiss Alps): Melting glaciers have revealed the remains of two Belgian hikers missing since 1992, underscoring how warming conditions are exposing long-buried risks and tragedies.

Locarno Industry Spotlight: Swiss Films previewed six feature projects for 2026–2027, including a drama tied to Swissair Flight 111 and a Ticino social drama, with several still seeking premieres and international distribution. Nursing Safety in Crises: On World Humanitarian Day, the International Council of Nurses launched a new #NursesforPeace bulletin urging an urgent end to attacks on health professionals and calling for stronger protection under international law. Stroke Rehab Roadmap: An international task force outlined a precision stroke recovery plan using genetic and blood biomarkers to guide next-generation rehabilitation and biotherapies. Assisted Dying Debate: France’s assisted dying law took effect after constitutional approval, allowing eligible adults to self-administer a lethal substance with doctor checks and a waiting period. Swiss Migration Update: Switzerland’s Federal Administrative Court said some Afghan refugees can be returned in limited cases if “favorable individual circumstances” apply, while keeping returns restricted. Climate-Linked Human Remains: In Valais, police identified two Belgian climbers missing since 1992 after bodies were found on the melting Trift Glacier.

Workplace Safety: Switzerland-based Condair Group faces a proposed $40,000 fine after Virginia regulators said workers were exposed to a toxic chemical without required safety steps. Assisted Dying Law: France’s Constitutional Council ruled private hospitals can opt out of assisted suicide/euthanasia if it conflicts with their mission, while state-run facilities must still comply. Biosimilars & Pharma Deals: Henlius and Sandoz announced a global biosimilar commercialization collaboration (up to $322m), and AstraZeneca reported a lung-cancer win with Tagrisso plus Orpathys. Air Quality & Health: Indonesian wildfires pushed haze into Malaysia, driving air pollution to “very unhealthy” levels and triggering school closures. Human Rights (UN): UN Committee against Torture found Morocco violated the Convention against Torture over degrading detention conditions for Sahrawi defender Abdelmoula El Hafidi in Aït Melloul Prison. Tech & Data Governance: Swiss firms are accelerating Microsoft AI adoption with stronger governance and data sovereignty controls, according to ISG. Public Health & Screens: A WHO HBSC study links Switzerland with among the most successful teen screen-time outcomes, while Israel’s “social media addiction” rose sharply.

Heatwave & health protection: Swiss NGOs have launched “No 50°C summers!” urging immediate climate action and stronger heatwave safeguards for vulnerable people, schools and workplaces, plus more green spaces and support for drought-hit farmers. Swiss policy & mobility: The Swiss Senate’s Political Institutions Committee proposes an “immigration tax” tied to the Switzerland–EU safeguard clause, collected from employers and aimed at encouraging use of the domestic labour force. Rare disease drug outlook: Santhera says it is nearing cash break-even as AGAMREE (vamorolone) gains traction in Duchenne muscular dystrophy, with planned Spain/Italy launches in late 2026. Cancer diagnostics market: A new report projects the global cancer biomarkers market to more than double by 2032, driven by early detection and precision medicine. Aviation services: Swissport marks its 30th anniversary, highlighting growth and increased investment in AI, automation and electric ground support equipment. Public health & environment: A Japanese beetle alert is in the EU, noting the pest is already present in parts of Switzerland and can damage gardens and crops. Health & community: A Swiss-linked charity trek (Tour du Mont Blanc) is raising funds for colorectal cancer services.

Diagnostics & Precision Medicine: Sonic Healthcare is widening its diagnostics footprint, taking a meaningful stake in microbiome testing specialist Microba Life Sciences and expanding its German lab network via acquisition. Hearing Tech Meets Medicine: Samsung says the FDA cleared a Galaxy Buds “hearing aid” feature for adults with mild-to-moderate hearing loss, with a hearing test built into the devices—though Europe isn’t confirmed yet. Cancer Drug Update: The FDA granted accelerated approval to iberdomide (Zenbexus) for relapsed/refractory multiple myeloma after at least one prior treatment line. Pharma Partnerships: Henlius and Sandoz announced a strategic collaboration covering up to 10 biosimilar candidates, valued up to $322m. Swiss Climate & Health Risk: Swiss cities are pushing for federal backing to adapt to heatwaves, as drought and extreme heat also hit local food producers like cheese makers. Public Health Funding Shock: Handicap International warns that sharp cuts to international aid are severely harming people with disabilities, with many programmes being cancelled. Care Access & Policy Debate: A new discussion weighs the affordability and tradeoffs of universal health coverage, using Switzerland and other countries as reference points.

Heat & food security: Swiss cheese makers say heat waves and drought are cutting cow milk output and worsening fodder shortages, with Gruyère production expected to drop about 10% without a quick return of rain. Urban climate planning: The Swiss Cities Association is urging a nationwide framework (not just local fixes) to coordinate heat-wave adaptation, including cooling for hospitals and schools, more greenery, and less paving. Workforce & pay: Swiss unions are pushing for a 2% general wage rise for 2027, while employers argue for closer to 1%, with healthcare unions citing years of weak wage growth. HIV treatment safety (Switzerland-linked): A Swiss HIV Cohort Study analysis finds switching to integrase-based therapy may slightly raise cardiovascular risk at 1 year, but not over 6 years. Privacy & tech: OpenAI’s new ChatGPT “Computer History” for Mac logs user actions and stores them as unencrypted plain-text files, raising new privacy concerns. Cancer care: FDA accelerated approval adds iberdomide (Zenbexus) for multiple myeloma at first relapse, in combination therapy.

Swiss Biopharma Deal: Sandoz will pay up to $77m upfront to Shanghai Henlius Biotech for rights to three biosimilars targeting cholesterol, lupus and colorectal cancer, with global commercialization rights outside China. Alzheimer’s Research in Zurich: ETH Zurich professor Ursula Quitterer’s “Compound 10” (tested in mice) appears to slow Alzheimer’s-related nerve cell death by targeting GRK2, with results published in Cell Reports Medicine. Heat & Health Economics: A Reuters look at Europe’s record heat highlights a growing insurance gap: extreme heat disrupts operations and productivity, but often isn’t treated as a traditionally insured risk. Drug Access Pressure in Switzerland: Swiss pharma groups warn medicine access is worsening, as reimbursement and pricing frictions continue to affect innovative treatments. Public Health Tech Privacy: OpenAI’s new ChatGPT “Computer History” feature logs keystrokes and clicks on macOS, stores them as unencrypted plain text locally, and is not available in Switzerland/UK/EEA. Local Safety Incident: Switzerland’s Graubünden saw a fatal horse-drawn carriage crash: one woman died and 12 were injured after brake failure led to a collision with a tree.

Heat & climate adaptation: The Swiss Cities Association is urging a nationwide strategy to help municipalities adapt to climate change, warning many urban areas were built for weather that no longer exists and calling for structured funding plus coordination with cantons and the federal government. Public health & safety: A 73-year-old woman died and 12 others were injured in a horse-drawn tourist carriage crash in Val Roseg near Pontresina, after a driver couldn’t slow enough on a downhill stretch and lost control. Medicine access debate: Interpharma says Swiss medicine access is worsening, while a separate report says federal audits found Swiss hospitals fail to pass on discounts to patients. Digital privacy: OpenAI’s new ChatGPT “Computer History” feature logs clicks and keystrokes on macOS and stores them locally as unencrypted plain text, with availability restrictions for Switzerland/UK/EEA. Diabetes research: A study in the European Journal of Nutrition links daily non-sugar-sweetened drinks with a higher risk of developing type 2 diabetes. Assisted dying politics: A UK Labour MP argues palliative and social care funding must be fixed before any assisted suicide law debate.

Nursing Crisis in DRC: The International Council of Nurses (ICN) is urging the DRC health minister to urgently pay and protect nurses and health workers on the Ebola frontline, saying many have gone unpaid for months while facing serious risks. Swiss Health & Care Context: The ICN push lands as Switzerland remains closely tied to global health response efforts, with Swissmedic and Swiss institutions referenced in wider international medical coverage this week. End-of-Life Debate: A fresh wave of discussion around assisted dying continues, including commentary that points readers toward Switzerland for legal end-of-life options—highlighting how Swiss policy is shaping international conversations. Swiss Spotlight in Culture: Locarno Film Festival in Switzerland saw Florin Serban win the Golden Leopard and Monica Bellucci take an acting award, keeping Swiss public attention on health-adjacent themes like identity and care in film narratives. Sleep & Wellness: A University of Freiburg researcher in Switzerland explains the “first-night effect,” noting people often sleep less deeply in unfamiliar places.

Cancer Drug Update: The FDA granted accelerated approval to iberdomide (Zenbexus) for adults with relapsed or refractory multiple myeloma, in combination with daratumumab, hyaluronidase-fihj and dexamethasone—an oral option aimed at patients after at least one prior therapy line. Swiss Research & Care Access: Swissmedic is mentioned as part of the international Project Orbis review pathway, highlighting cross-border oncology regulation. Public Health & Safety: A Swiss sleep study report explains the “first-night effect,” where many people sleep less and wake more in unfamiliar places—an issue for travellers and shift workers. Medication & Patient Skills: A qualitative study on medication literacy after heart procedures points to gaps in how younger and middle-aged patients understand and manage post-PCI medicines. Policy Watch (Europe): France’s constitutional body upheld assisted-dying legislation, with safeguards—raising practical questions about palliative care access and oversight. Health Governance (Global): Cameroon President Paul Biya’s long absence, including time in Geneva, is renewing health-and-leadership concerns.

Heat & Learning Readiness: Swiss teachers’ unions warn that schools are ill-equipped for hot summers, saying rising temperatures can hurt concentration and learning and that ad-hoc fixes aren’t enough. Public Health & Medicines Access: Interpharma says Swiss medicine access is worsening, while a federal audit finds Swiss hospitals fail to pass on discounts to patients—raising concerns about affordability of care. Food & Metabolic Health: A study links higher intake of non-sugar-sweetened beverages to higher type 2 diabetes risk, especially for adults with higher BMI and some ethnic groups, and suggests “switching” drinks may not deliver the expected protection. Wearables for Emergencies: Google’s Pixel Watch 5 adds breathing emergency detection that can call emergency services if the wearer becomes unresponsive, extending the push toward proactive health tech. Local Policy on Speed Limits: The Federal Council sets new rules for lowering 30km/h limits on main roads, requiring proof traffic won’t spill into residential streets. Healthcare Expansion: Cencosud plans to expand Unicenter in Argentina with a Swiss Medical center offering outpatient care, diagnostics, and many specialties for over 20,000 patients per month.

Lyme vaccine push (EU/Switzerland): EU regulators have agreed to study an experimental Lyme disease vaccine from Pfizer and Valneva after trials reported about 70% efficacy in ages 5+; the EMA accepted the approval application, with companies pointing to large at-risk populations as tick seasons lengthen. Medicine access pressure (Switzerland): Interpharma says Swiss medicine access is worsening as drugmakers curb reimbursement applications amid pricing concerns. Alzheimer’s diagnostics (US, with Swiss links): Lantheus won FDA approval for TAUKLARIFY, a tau PET imaging agent to identify Alzheimer’s tau pathology in adults with cognitive impairment. Health tech research (Basel): University of Basel researchers are advancing PC-based control for a miniature surgical robot aimed at ultra-precise bone surgery and bio-ink implants. Wellness caution: French reporting highlights a growing trend of injecting banned peptides for “optimising” the body, with experts warning of limited proof and serious health risks. Public health & ageing: A Swiss-linked study finds poorer people experience faster declines in mobility and physical function in old age. Caregiver/health media: North Carolina marks the retirement of long-running physician broadcaster Dr. Allen Mask, blending clinical care with community health messaging.

Swiss Medicines Access: Interpharma says pharma groups are holding back on reimbursement submissions in Switzerland, linked to the US “Most Favoured Nation” pricing approach, with patient access to innovative drugs already worsening. FDA Watch: ADC Therapeutics reports the FDA has “substantial concerns” over benefit-risk for its ADC lymphoma trial, threatening a path from accelerated to full approval. Cancer Prevention: Scientists are testing vaccines aimed at stopping Lynch-syndrome colon cancer before tumors form, with early trials underway in the US and Britain. Health Equity: A PLOS Medicine study finds poorer older adults in England and Canada lose mobility and physical function up to 15 years earlier than wealthier peers. Wellness Caution: A growing trend of injecting banned peptides for “optimisation” is raising safety concerns, with experts warning evidence is thin and risks are real. Swiss Pharma Court: Novartis wins a UK court battle to uphold the Entresto patent, protecting the blockbuster from generic challenge. Climate & Health Risk: Europe braces for another major heatwave; Western Europe’s June–July temperatures are reported well above average, with heat linked to thousands of deaths.